FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or antigen-binding fragment that specifically binds to tumour necrosis factor 2 (TNFR2); to a pharmaceutical composition and a set for cancer treatment containing the said antibody; a method for treating a disease associated with an immune disorder; to the use of said antibody, or an antigen-binding fragment thereof, or a pharmaceutical composition for the manufacture of a medicament for the treatment of a disease associated with an immune disorder; to a method for detecting soluble TNFR2 (sTNFR2) using the said antibody.
EFFECT: invention makes it possible to regulate the function of immune cells and can be used as a drug for the treatment of diseases associated with immune disorders, such as a tumor.
16 cl, 14 dwg, 10 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| NEW ANTI-PRESEPSIN ANTIBODY | 2015 |
|
RU2710439C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
